We did not find evidence of co-occurrence of the DNA repair and chromatin remodeling genomic alterations as observed in the capecitabine exceptional responders in the TCGA ER-positive, HER2-negative primary breast cancers, suggesting that coexpression of these alterations is uncommon. This evidence concerns the gene ERBB2 and breast carcinoma.